



New York State Medicaid Drug Utilization Review (DUR) Board Meeting Agenda – November 5, 2020

The DUR Board will meet on November 5, 2020, from 9:00 a.m. to 4:00 p.m.

There will be no in-person meeting. The meeting will be available for public viewing by way of a live audio-video webcast. The link to the webcast is available from the Department of Health Events/Webcasts webpage.

<https://www.health.ny.gov/events/webcasts/>

Please monitor this boxed area for any scheduling or webcast changes.

https://www.health.ny.gov/health_care/medicaid/program/dur/index.htm

A. Preferred Drug Program (PDP)

The DUR Board will review therapeutic classes listed below, as they pertain to the PDP.

- The DUR Board will review clinical and financial information, to recommend preferred and non-preferred drugs.
- For therapeutic classes currently subject to the PDP, the DUR Board will only consider clinical information which is new since the previous review of the therapeutic class and then consider financial information.

New clinical information may include a new drug or drug product information, new indications, new safety information or new published clinical trials (comparative evidence is preferred, or placebo controlled when no head-to-head trials are available). Information in abstract form alone, posters, or unpublished data are poor quality evidence for the purpose of PDP reviews and submission is discouraged.

- The current preferred and non-preferred status of drugs subject to the Preferred Drug List (PDL) may be viewed at:

https://newyork.fhsc.com/downloads/providers/NYRx_PDP_PDL.pdf

1. ARBs Combinations
(Previous review date: 09/15/2016)
2. Antimigraine Agents – Acute Treatment
(Previous review date: 09/15/2016)
Includes a review of drug utilization and clinical criteria

3. Antipsychotics – Second Generation
(Previous review date: 04/27/2017)
4. Multiple Sclerosis Agents
(Previous review date: 05/16/2019)
5. Gastrointestinal Antibiotics
(Previous review date: 06/27/2013)
6. Immunomodulators- Systemic
(Previous review date: 09/20/2018)

B. Drug Utilization Reviews

The DUR Board will review the following topics and, if applicable, recommend clinical criteria and/or interventions to ensure appropriate drug utilization:

1. Opioids used for the treatment of acute pain and morphine milligram equivalent (MME) parameters.
2. Long Acting Injectable Antipsychotic utilization as related to the SUPPORT Act[^].
[^]Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act.
<https://www.congress.gov/115/bills/hr6/BILLS-115hr6enr.pdf>

Agenda Timeline (subject to change based on meeting proceedings)

9:00 - 9:15	Welcome and Opening Comments
9:15 - 10:45	Public Comment Period
10:45 - 12:00	PDP Clinical Reviews
12:00 - 1:00	Lunch/Executive Session (PDP Financial Reviews)
1:00 - 1:30	PDP Recommendations
1:30 - 3:30	Drug Utilization Reviews
3:30 - 4:00	Final Comments and Adjournment

Interested parties must submit a request to provide public comment during the DUR Board meeting and complete the registration process by October 25, 2020. Requests to provide public comment may be made by calling 518-486-3209 or e-mailing dur@health.ny.gov (please reference DUR Board Meeting Speaker Request).

Public comments are limited to the items on the agenda. Comments must be brief (2 minutes) and the total comment period will not exceed ninety (90) minutes. The Department of Health (DOH) reserves the right to limit the number of interested parties providing public comment in order to meet meeting timelines and accomplish meeting objectives.

Clinical information must be received in an electronic format by October 21, 2020 or the DUR Board may not have ample time to review the information. General written statements must be received in an electronic format by October 25, 2020 and should summarize key points and may not exceed two (2) pages in length. Any studies cited should be referenced, with the primary source of funding included.

All information must be sent to the DOH. Interested parties should not contact or send any information directly to DUR Board members.